Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Catalent entering gene therapy market via Paragon buy

Catalent Inc. will buy privately held Paragon Bioservices Inc. for $1.2 billion in cash, bolstering the contract drugmaker’s capabilities to make gene therapy drugs for biotech clients.

Read More »

Bristol-Myers shareholders approve Celgene takeover

Bristol-Myers Squibb’s shareholders voted to approve the drugmaker’s $74 billion takeover of Celgene despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

Read More »

Novo Nordisk, Gilead team up to test NASH treatment

Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.

Read More »

Gilead Sciences Cuts 150 Sales Jobs

The loss of patent protection on two drugs is forcing Gilead Sciences to terminate about 20 percent of the company’s sales team, according to reports.

Read More »

AskBio Snags $235 Million Investment to Drive Gene Therapy Development

Asklepios BioPharmaceutical (AskBio) secured a $235 million investment from Vida Ventures and TPG Capital.

Read More »

Fresenius Expands Manufacturing Presence in North Carolina, to Add 445 New Jobs

Fresenius Kabi is investing $100 million in expanding the German company’s manufacturing campus in Wilson County, North Carolina, which will add at least 445 new jobs.

Read More »

U.S. charges 24 in telemedicine healthcare fraud resulting in losses of $1.2+ billion

U.S. authorities said 24 defendants were charged in connection with one of the largest healthcare fraud schemes prosecuted by the federal government, involving telemedicine companies and resulting in more than $1.2 billion of losses.

Read More »

Regeneron forays into gene-silencing therapies with Alnylam tie-up

Regeneron Pharmaceuticals is investing $800 million in Alnylam Pharmaceuticals to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference technology.

Read More »

Merrimack Scraps Solid Tumor Asset

Shares of Merrimack Pharmaceuticals sunk after the company announced the discontinued development of an experimental solid tumor treatment and will lay off some employees.

Read More »

Roivant and Sinovant Launch Cytovant

Vivek Ramaswamy’s Roivant Sciences has launched another “vant” company, this time in China, in a partnership with Hong Kong-based Sinovant Sciences.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom